Reported Saturday, REGENXBIO Presents Favorable Long-Term Data For Sura-Vec Showing Stable To Improved Vision Through 5 Years In Wet AMD And 2.5-Year Efficacy In Diabetic Retinopathy At ASRS Annual Meeting

뉴스 본문을 불러오고 있어요.

Reported Saturday, REGENXBIO Presents Favorable Long-Term Data For Sura-Vec Showing Stable To Improved Vision Through 5 Years In Wet AMD And 2.5-Year Efficacy In Diabetic Retinopathy At ASRS Annual Meeting | 웨이프 WAPE

Reported Saturday, REGENXBIO Presents Favorable Long-Term Data For Sura-Vec Showing Stable To Improved Vision Through 5 Years In Wet AMD And 2.5-Year Efficacy In Diabetic Retinopathy At ASRS Annual Meeting

기사 요약

관련 종목

댓글 —